Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients
Section snippets
Methods
We performed a retrospective cohort study investigating lung transplant recipients in the Scientific Registry of Transplant Recipients (SRTR) aged ≥65 years from May 2005 to March 2018. Our analysis cohort included 5,815 adult first-time lung transplant recipients aged ≥65 years (Figure 1). The study was approved by the institutional review board (Pro00101865) at the Duke University Medical Center, Durham, NC.
Recipient and donor characteristics at the time of transplantation were described
Characteristics of analysis cohort
Among the entire study cohort of 5,815 lung transplant recipients aged ≥65 years, the median (Q1, Q3) age was 68 (66, 70) years, and subjects were predominately male (69%), white (89%), and single lung transplant recipients (55%) with native restrictive lung disease (68%) (Table 1). When stratified by age, the majority were in the 65 to 69 age stratum (73%). The most common comorbidities were chronic hypoxemic respiratory failure (91%), obesity defined as body mass index >30 kg/m2 (17%), and
Discussion
We conducted an analysis of survival outcomes and risk factors for mortality in individuals aged ≥65 years undergoing lung transplantation. Median survival in the 5,815 lung transplant recipients aged ≥65 years was 4.41 years. This survival is reduced when compared with a median of 6.5 years among those aged 35 to 49 years.9 In the multivariable model, increasing recipient age strata, creatinine level, bilirubin level, hospitalization at the time of transplantation, single lung transplantation,
Disclosure statement
C.L.M. receives research support from the National Institutes of Health (NIH) (5T32HL007538-35) and the CHEST Foundation. The remaining authors have no conflicts of interest to disclose.
The authors thank the Scientific Registry of Transplant Recipients (SRTR) for the use of the SRTR patient registry data to conduct this study. In addition, the authors thank the patients, care providers, and clinical coordinators at SRTR reporting centers throughout the United States for their contributions to
Author contributions
Concept and design: C.L.M., J.M.W., M.L.N., S.M.P.
Acquisition, analysis, or interpretation of data: C.L.M., J.M.W., M.L.N., S.M.P., C.W.F.
Drafting of the manuscript: C.L.M., J.M.W., M.L.N., S.M.P.
Critical revision of the manuscript for important intellectual content: C.L.M., J.M.W., M.L.N., C.W.F, S.M.P.
Statistical analysis: J.M.W., M.L.N.
Administrative, technical, or material support: S.M.P.
Supervision: S.M.P.
References (18)
- et al.
A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
(2015) - et al.
Extremes of age decrease survival in adults after lung transplant
Chest
(2020) - et al.
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation
J Heart Lung Transplant
(2018) - et al.
The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report–2013; focus theme: age
J Heart Lung Transplant
(2013) - et al.
What is the optimal transplant for older patients with idiopathic pulmonary fibrosis?
Ann Thorac Surg
(2015) - et al.
Influence of age on survival in adult patients on extracorporeal membrane oxygenation before lung transplantation
J Heart Lung Transplant
(2015) - et al.
Frailty in the end-stage lung disease or heart failure patient: implications for the perioperative transplant clinician
J Cardiothorac Vasc Anesth
(2019) - et al.
Frailty phenotypes and mortality after lung transplantation: a prospective cohort study
Am J Transplant
(2018) - et al.
Survival benefit of lung transplantation in the modern era of lung allocation
Ann Am Thorac Soc
(2017)
Cited by (20)
Cardiothoracic Transplant Anesthesia: Selected Highlights: Part I—Lung Transplantation
2023, Journal of Cardiothoracic and Vascular AnesthesiaTriaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome
2023, Journal of Heart and Lung TransplantationListing Dilemmas: Age, Frailty, Weight, Preexisting Cancers, and Systemic Diseases
2023, Clinics in Chest MedicineReal-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients
2022, Journal of Heart and Lung TransplantationCitation Excerpt :Cytomegalovirus (CMV) is a major contributor to morbidity and mortality in lung transplant recipients (LTR), associated with both clinical disease and chronic lung allograft dysfunction (CLAD).1-7
The Year in Cardiothoracic Transplant Anesthesia: Selected Highlights From 2020 Part I – Lung Transplantation
2022, Journal of Cardiothoracic and Vascular AnesthesiaCitation Excerpt :Approximately 30% of patients who had undergone LTX after 2016 were 65 years and older. Mosher et al analyzed risk factors associated with mortality in this group of patients.62 They reported that the majority of patients in the Medicare-eligible age group were male, White, and often underwent single LTX in high-volume centers.